|
FSGS
Trials: The Details
Number of Patients: 500
Eligibility
Medications
All
patients to receive alternative day oral prednisone,
PLUS an angiotensin receptor blocker (ARB),
PLUS an ACE inhibitor.
Half
the patients, in random selection, will receive
the immunosuppressant cyclosporine. The other
half will receive the immunosuppressant mycophenolate
mofetil (MMF, brand name CellCept) and pulse
treatments of dexamethasone, a synthetic adrenocortical
steroid.
Five
Core Clinical Centers
State
University of New York, Stony Brook; Montefiore
Medical Center, Bronx, N.Y.; SeattleChildren's
Medical Center; Medical City Dallas Hospital;
and the University of North Carolina.The data-coordinating
center is the Cleveland Clinic, and NephCure
will fund ancillary studies.
Start
Date: Nov. 1, 2003
Estimated
Cost: $12 Million
|
